The latest overall survival analysis of the HEAT Study, which is evaluating ThermoDox and radiofrequency ablation in hepatocellular carcinoma, showed that a subgroup of patients demonstrated an average 58 percent improvement in overall survival.
A phase II study of atezolizumab immunotherapy met its primary endpoint, shrinking tumors in patients with locally advanced or metastatic non-small cell lung cancer whose disease expressed PD-L1.
A statistically significant percentage of chronic lymphocytic leukemia patients in a phase II clinical trial responded to venetoclax therapy.
The National Cancer Institute Cancer Therapy Evaluation Program approved the following clinical research studies last month. For further information, contact the principal investigator listed.
Study: Robotic Surgery Shows Long-term Results Similar to Traditional Open Surgery in Bladder Cancer
In the largest multi-institutional study to date, patients diagnosed with bladder cancer and treated with robot-assisted surgery experienced similar results to those who underwent a traditional open operation, according to research led by scientists at Roswell Park Cancer Institute.
Updated results from a phase II study of elderly patients with newly diagnosed acute myeloid leukemia showed that to date, in 50 patients treated with Pracinostat in combination with azacitidine (Vidaza), 27 patients achieved complete response, plus complete response with incomplete blood count recovery plus morphologic leukemia-free state, including 16 patients who achieved a CR.
A phase III trial of Cyramza (ramucirumab) as a second-line treatment for hepatocellular carcinoma failed to meet its primary endpoint of overall survival.
A phase III study of Vectibix (panitumumab) in metastatic colorectal cancer met its primary endpoint of improving overall survival.
As many as 40 percent of patients with lower-risk prostate cancers may be currently receiving overtreatment, according to researchers that examined common treatment practices.
FDA approved Odomzo (sonidegib) capsules for the treatment of patients with locally advanced basal cell carcinoma that has recurred following surgery or radiation therapy, or those who are not candidates for surgery or radiation therapy. Odomzo is marketed by Novartis Pharmaceuticals Corp.
